logo
ASX health April winners and losers: Sector rises 2pc in stronger month for markets

ASX health April winners and losers: Sector rises 2pc in stronger month for markets

News.com.au04-05-2025
The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6%
Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months
Several approvals during April, including for EBR and Orthocell, helped boost sentiment in the sector
The S&P/ASX 200 Health Care Index was stronger in April, rising 2.16% after being the second-worst performing sector in March.
Healthcare followed the broader market upward with the S&P/ASX 200 rallying 3.6% in April as the local bourse held firm against ongoing global geopolitical tensions and economic headwinds.
Morgans healthcare analyst Iain Wilkie told Stockhead April was a marked improvement on recent months, partly due to US President Donald Trump softening his stance on tariffs late in April and easing tensions around a potential trade war with China.
Wilkie said April marked a solid month of regulatory approvals with EBR Systems (ASX:EBR) gaining US FDA approval for its WISE CRT system – the world's first and only wireless solution for pacing the left side of the heart.
Orthocell (ASX:OCC) scored a hattrick of three regulatory approvals in April for its flagship nerve repair product Remplir, including in Canada, Thailand and the US markets.
The latest approvals add to pre-existing approvals for Remplir in Australia, New Zealand and Singapore, equating to a significant total addressable market of US$1.8 billion. Regulatory applications for the EU and UK are on track to be submitted in the next six to 12 months.
Wilkie said the approvals were also reassuring amid concerns about recent changes at the FDA with reported mass layoffs under Tesla CEO and billionaire Elon Musk's Department of Government Efficiency (DOGE), which were quickly followed by a partial rehiring.
"It's good momentum for the sector and shows approvals are still getting through the FDA in time," Wilkie said.
"We will see what happens in the next few months."
How ASX biotechs performed in April
CODE COMPANY PRICE 1 MONTH RETURN % MARKET CAP
ICR Intelicare Holdings $ 0.01 66.7% 4
NSB Neuroscientific $ 0.05 35.1% 7
AVR Anteris Technologies $ 8.55 31.5% 270
CC5 Clever Culture $ 0.02 28.6% 30
SHG Singular Health $ 0.30 22.9% 77
CHM Chimeric Therapeutic $ 0.01 20.0% 14
IXC Invex Ther $ 0.08 19.1% 6
4DX 4Dmedical Limited $ 0.32 18.5% 135
IMR Imricor Med Sys $ 1.62 17.4% 476
COV Cleo Diagnostics $ 0.41 17.1% 52
DVL Dorsavi Ltd $ 0.01 16.7% 5
DXB Dimerix Ltd $ 0.48 15.7% 425
IDT IDT Australia Ltd $ 0.12 15.0% 49
PME Pro Medicus Limited $ 229.41 14.8% 24,998
AVH Avita Medical $ 3.10 14.0% 369
LDX Lumos Diagnostics $ 0.03 12.5% 21
PGC Paragon Care Limited $ 0.42 12.0% 712
EYE Nova EYE Medical Ltd $ 0.11 10.0% 31
1AI Algorae Pharma $ 0.01 9.1% 10
ECS ECS Botanics Holding $ 0.01 8.3% 16
MVP Medical Developments $ 0.60 8.1% 71
AHX Apiam Animal Health $ 0.41 8.0% 79
ALA Arovella Therapeutic $ 0.09 7.5% 103
OCC Orthocell Limited $ 1.60 6.7% 391
AT1 Atomo Diagnostics $ 0.02 5.9% 13
PNV Polynovo Limited $ 1.21 5.7% 888
IDX Integral Diagnostics $ 2.42 5.7% 871
NAN Nanosonics Limited $ 4.80 5.5% 1,486
CYP Cynata Therapeutics $ 0.20 5.4% 44
VBS Vectus Biosystems $ 0.08 5.3% 4
RHT Resonance Health $ 0.04 5.1% 16
RMD ResMed Inc. $ 36.68 4.9% 54,516
ALC Alcidion Group Ltd $ 0.09 4.9% 117
SIG Sigma Health Ltd $ 3.02 4.9% 35,436
ACL Au Clinical Labs $ 3.12 4.7% 621
COH Cochlear Limited $ 274.59 4.7% 17,937
OCA Oceania Healthc Ltd $ 0.57 4.6% 424
HLS Healius $ 1.46 4.3% 1,106
CU6 Clarity Pharma $ 2.20 4.3% 850
FPH Fisher & Paykel H. $ 31.51 4.2% 19,006
SNZ Summerset Grp Hldgs $ 10.55 4.1% 2,537
TRU Truscreen $ 0.03 3.7% 16
ARX Aroa Biosurgery $ 0.44 3.5% 159
TLX Telix Pharmaceutical $ 27.13 2.3% 9,853
AFP Aft Pharmaceuticals $ 2.34 1.7% 245
CYC Cyclopharm Limited $ 1.17 1.7% 133
SHL Sonic Healthcare $ 26.08 1.2% 12,538
CSL CSL Limited $ 251.13 0.7% 123,518
REG Regis Healthcare Ltd $ 6.81 0.7% 2,208
PCK Painchek Ltd $ 0.04 0.0% 66
SPL Starpharma Holdings $ 0.09 0.0% 38
AVE Avecho Biotech Ltd $ 0.01 0.0% 16
VFX Visionflex Group Ltd $ 0.00 0.0% 10
ACR Acrux Limited $ 0.02 0.0% 9
EPN Epsilon Healthcare $ 0.02 0.0% 8
IVX Invion Ltd $ 0.10 0.0% 8
PAB Patrys Limited $ 0.00 0.0% 5
TD1 Tali Digital Limited $ 0.00 0.0% 3
OSX Osteopore Limited $ 0.02 0.0% 3
IMC Immuron Limited $ 0.07 -0.7% 15
CUV Clinuvel Pharmaceut. $ 11.36 -0.9% 580
BOT Botanix Pharma Ltd $ 0.45 -1.1% 904
EBO Ebos Group Ltd $ 34.20 -1.2% 7,017
NOX Noxopharm Limited $ 0.08 -1.2% 22
M7T Mach7 Tech Limited $ 0.34 -1.5% 84
ONE Oneview Healthcare $ 0.29 -1.7% 216
RAC Race Oncology Ltd $ 1.05 -1.9% 212
CTE Cryosite Limited $ 0.78 -1.9% 38
PTX Prescient Ltd $ 0.05 -2.1% 38
NEU Neuren Pharmaceut. $ 11.66 -2.3% 1,573
SDI SDI Limited $ 0.84 -2.3% 100
RHC Ramsay Health Care $ 33.26 -2.5% 7,860
VHL Vitasora Health Ltd $ 0.04 -2.6% 60
MYX Mayne Pharma Ltd $ 7.03 -2.8% 571
ILA Island Pharma $ 0.16 -3.0% 38
MX1 Micro-X Limited $ 0.06 -3.2% 37
IMM Immutep Ltd $ 0.27 -3.6% 394
OIL Optiscan Imaging $ 0.14 -3.6% 113
PYC PYC Therapeutics $ 1.18 -3.7% 714
IRX Inhalerx Limited $ 0.03 -3.8% 5
CGS Cogstate Ltd $ 1.33 -4.3% 227
VLS Vita Life Sciences.. $ 1.82 -4.5% 99
AGH Althea Group $ 0.02 -4.5% 19
AHC Austco Healthcare $ 0.28 -5.1% 100
TRJ Trajan Group Holding $ 0.81 -5.3% 128
HMD Heramed Limited $ 0.02 -5.3% 15
EMV Emvision Medical $ 1.96 -6.2% 164
NYR Nyrada Inc. $ 0.10 -7.0% 23
TRI Trivarx Ltd $ 0.01 -7.1% 7
IPD Impedimed Limited $ 0.04 -7.3% 71
NUZ Neurizon Therapeutic $ 0.12 -7.7% 69
EZZ EZZ Life Science $ 1.43 -7.7% 65
LGP Little Green Pharma $ 0.12 -8.0% 36
MSB Mesoblast Limited $ 1.80 -8.4% 2,367
BMT Beamtree Holdings $ 0.22 -8.5% 62
PSQ Pacific Smiles Grp $ 1.76 -8.6% 284
IIQ Inoviq Ltd $ 0.37 -8.6% 45
NXS Next Science Limited $ 0.10 -9.1% 26
PER Percheron $ 0.01 -9.1% 10
EMD Emyria Limited $ 0.03 -9.7% 15
ANN Ansell Limited $ 30.30 -10.5% 4,512
ATH Alterity Therap Ltd $ 0.01 -11.1% 78
OSL Oncosil Medical $ 0.00 -11.1% 16
CMP Compumedics Limited $ 0.31 -11.6% 58
AGN Argenica $ 0.68 -11.8% 93
MDR Medadvisor Limited $ 0.10 -12.7% 57
PAR Paradigm Bio. $ 0.29 -13.6% 121
VIT Vitura Health Ltd $ 0.07 -13.8% 48
TYP Tryptamine Ltd $ 0.03 -13.9% 45
BIT Biotron Limited $ 0.00 -14.3% 4
BP8 Bph Global Ltd $ 0.00 -14.3% 1
IME Imexhs Limited $ 0.34 -15.0% 17
NC6 Nanollose Limited $ 0.03 -15.0% 9
ACW Actinogen Medical $ 0.03 -15.6% 83
DOC Doctor Care Anywhere $ 0.08 -15.8% 30
UBI Universal Biosensors $ 0.06 -15.9% 16
AYA Artryalimited $ 0.63 -16.0% 76
EOF Ecofibre Limited $ 0.02 -16.0% 7
TRP Tissue Repair $ 0.22 -17.0% 12
MAP Microbalifesciences $ 0.17 -17.1% 82
CSX Cleanspace Holdings $ 0.39 -17.2% 29
ZLD Zelira Therapeutics $ 0.38 -17.4% 5
LTP Ltr Pharma Limited $ 0.38 -18.5% 73
RCE Recce Pharmaceutical $ 0.29 -18.7% 78
IBX Imagion Biosys Ltd $ 0.01 -18.8% 3
SOM SomnoMed Limited $ 0.45 -18.9% 95
GSS Genetic Signatures $ 0.41 -19.0% 110
CVB Curvebeam Ai Limited $ 0.10 -20.0% 39
CBL Control Bionics $ 0.04 -20.0% 11
CTQ Careteq Limited $ 0.01 -20.0% 3
GLH Global Health Ltd $ 0.09 -21.7% 5
RAD Radiopharm $ 0.02 -22.2% 51
CDX Cardiex Limited $ 0.06 -22.7% 23
UCM Uscom Limited $ 0.02 -23.3% 6
RGT Argent Biopharma Ltd $ 0.13 -23.5% 8
RHY Rhythm Biosciences $ 0.06 -23.8% 19
NTI Neurotech Intl $ 0.03 -24.2% 25
CMB Cambium Bio Limited $ 0.23 -24.6% 4
BDX Bcaldiagnostics $ 0.08 -24.9% 30
IMU Imugene Limited $ 0.02 -25.0% 172
1AD Adalta Limited $ 0.01 -25.0% 4
FRE Firebrickpharma $ 0.07 -25.3% 15
MVF Monash IVF Group Ltd $ 0.84 -26.0% 334
SNT Syntara Limited $ 0.06 -26.3% 99
PIQ Proteomics Int Lab $ 0.36 -28.0% 54
ANR Anatara Ls Ltd $ 0.01 -28.6% 1
ATX Amplia Therapeutics $ 0.05 -30.0% 21
EBR EBR Systems $ 1.22 -30.3% 464
PEB Pacific Edge $ 0.08 -31.8% 61
HIQ Hitiq Limited $ 0.03 -32.4% 11
CAN Cann Group Ltd $ 0.02 -36.0% 10
ADR Adherium Ltd $ 0.01 -36.4% 5
MEM Memphasys Ltd $ 0.01 -44.4% 12
NeuroScientific Biopharmaceuticals (ASX:NSB) rose 35.1% after sealing a deal to acquire StemSmart, a patented stem cell tech from Isopogen WA, giving it full rights to produce next-generation cell therapies using mesenchymal stromal cells (MSCs).
Early trial results in Crohn's patients are promising, showing the treatment is safe, effective, and potentially life-changing. To fund the move, NeurosScientific has raised $3.5 million. It also has refreshed its board, including industry veterans and a new chief scientific adviser.
Oncology drug developer Chimeric Therapeutics (ASX:CHM) was up 20% in April. The company announced that Emory Winship Cancer Institute in Atlanta was open to enrol patients in the phase 1/2 multi-centre clinical trial (NCT06055439) for CHM CDH17 cell therapy.
The phase 1/2 trial is a two-stage study designed to determine a recommended phase II dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumours (NETs).
Imricor Medical Systems (ASX:IMR) also had a strong month, up 17.4% after positive news including launching its pivotal European clinical trial for ventricular tachycardia (VISABL-VT) – marking a series of world-first milestones – and securing CE Mark certification for its Advantage-MR system under the European Union's new Medical Device Regulation (MDR).
Imricor is pioneering real-time interventional cardiac MRI (iCMR) ablations – using MRI instead of traditional x-ray fluoroscopy to treat cardiac arrhythmias faster, safer and more effectively.
Health-imaging stock ProMedicus (ASX:PME) was up 14.8% in April. The company announced owned US subsidiary Visage Imaging, Inc. had signed a multi-year research collaboration deal with UCSF.
"I think ProMedicus just got oversold and it went down to around $150 at one point from just shy of $300," Wilkie said.
"These sorts of quality stocks always come back to the fore."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Regulator zeros in on Bally's Star rescue deal
Regulator zeros in on Bally's Star rescue deal

AU Financial Review

time7 hours ago

  • AU Financial Review

Regulator zeros in on Bally's Star rescue deal

Star Entertainment's rescue plan could be under threat with the NSW casino regulator warning it will closely examine the finances and leadership of Bally's Corporation before allowing it to take control. The American gaming giant will control Star, which operates casinos in Sydney, Brisbane and the Gold Coast, after providing a $300 million lifeline earlier this year. It has already flagged its intention of overhauling management as part of a turnaround plan and Bally's chairman Soo Kim is expected to join the board of the ASX-listed gaming group.

Wall Street inches up amid Trump EU trade remarks
Wall Street inches up amid Trump EU trade remarks

Perth Now

time11 hours ago

  • Perth Now

Wall Street inches up amid Trump EU trade remarks

The S&P 500 and the Dow edged up in tepid trading as investors assessed President Donald Trump's latest comments on trade discussions with the European Union and his hints that a rate cut from the US Federal Reserve was imminent. Trump said the odds of a US-EU trade deal were "50-50" and suggested after a meeting with Fed Chair Jerome Powell that a rate cut might be on the horizon. A spate of upbeat second-quarter earnings also supported Wall Street's record run. In early trading on Friday, the Dow Jones Industrial Average rose 70.76 points, or 0.16 per cent, to 44,764.67 - creeping up towards its December 4 record high. The S&P 500 added 10.70 points, or 0.17 per cent, to 6,374.05, and the Nasdaq Composite gained 1.87 points, or 0.01 per cent, to 21,059.83. Expectations were rife that the European bloc would soon sign an agreement with Washington. Meanwhile, US negotiations with South Korea gathered momentum ahead of the August 1 deadline set for most countries as they scrambled to avoid Trump's steep import levies. A wave of trade agreements including pacts with Japan, Indonesia and the Philippines set all three major indexes on track for a strong weekly finish, if the gains hold. Tariffs have had only a small impact on inflation and the economy has not shown many negative effects from shifts in trade policy, according to Paul Ashworth, chief North America economist at Capital Economics. Because of this, he said, even a slight increase in inflation would likely be enough to keep the Fed from cutting rates again. Of the 168 companies in the S&P 500 that have reported earnings as of Friday, 79.8 per cent beat analyst expectations, according to data compiled by LSEG. However, there were a few setbacks during the week. Heavyweights Tesla and General Motors stumbled and were on track for their steepest weekly declines in nearly two months if losses hold. Tesla CEO Elon Musk warned of tougher quarters ahead amid shrinking US EV subsidies, while General Motors took a hit after absorbing a $US1.1-billion ($A1.7 billion) blow in its second-quarter earnings from Trump's tariffs. Intel dropped 9.0 per cent after the chipmaker forecast steeper third-quarter losses than the Street expected and announced plans to slash jobs. All eyes will be on the US Federal Reserve's monetary policy meeting next week, with bets indicating that policymakers are likely to keep interest rates unchanged as they evaluate the impact of tariffs on inflation. The central bank is under immense scrutiny from the White House, with President Trump leading a censure campaign against Chair Jerome Powell for not reducing borrowing costs, while often hinting that he would sack the top policymaker. In a surprise move, Trump escalated the pressure by making a rare visit to the Fed headquarters on Thursday, where he criticised its $US2.5-billion ($A3.8 billion) renovation project. According to CME's FedWatch tool, traders now see a nearly 61.8 per cent chance of a rate cut as soon as September. Among other stocks, Newmont added 7.4 per cent after the gold miner surpassed Wall Street expectations for second-quarter profit. Health insurer Centene posted a surprise quarterly loss, but its shares gained 3.0 per cent. Paramount Global rose 2.1 per cent after US regulators approved its $US8.4 billion ($A12.8 billion) merger with Skydance Media.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store